Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting March 4, 2009

Size: px
Start display at page:

Download "Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting March 4, 2009"

Transcription

1 CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting March 4, 2009 Location: Learning Resource Center 3550 Mills Civic Parkway West Des Moines, Iowa Time: 9:30 a.m. 1:30 p.m. Final Agenda 1. Welcome & Introductions a) Commission Members and Staff b) Approval of the minutes c) Old business 2. Iowa Medicaid Enterprise Update(s) a) February 20 th Clinical Advisory Committee Report b) Other IME/DHS Updates 3. P&T Committee s Recommendations on Select Mental Health Drugs Report from February 13 th Mental Health Advisory Group meeting 4. Prior Authorization a) Extended Release Formulations Prior Authorization Criteria b) Modified Formulations Prior Authorization Criteria 5. Public Comment (See Conflict of Interest Disclosure Form) 6. ProDUR Edits: Quantity Limits List: acetaminophen-containing analgesics 7. Focus Studies/Provider Education Initiatives a) New Clozapine Users and Frequency of Monitoring Follow up b) Concurrent Inhaled Anticholinergics Initial Review c) Protease Inhibitors with HMG CoA Inhibitors Initial Review d) Thiazolidinediones in Congestive Heart Failure Initial Review e) Use of Metered Dose Inhalers vs. Nebulizers Initial Review 8. Public Comment IOWA MEDICAID ENTERPRISE ARMY POST ROAD - DES MOINES, IA 50315

2 9. Miscellaneous a) DUR Digest (Draft) 2009 Volume 21, Number 2 b) MedWatch 10. Executive Closed Session a) Approval of Minutes b) Review of Focus Studies Data with PHI c) Member Profiles 11. Adjournment Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to 5 minutes or less. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. For more information contact the DUR Director, Chad Bissell, Pharm.D. at info@iadur.org or (515)

3 Attachment 1 Summary of Non-Preferred Recommendations from November 13, 2008 P & T Committee Meeting Summary of P&T Recommendations 1. Nonpreferred: Pexeva, Metadate CD, Ritalin LA. 2. Nonpreferred with Conditions 1 : Seroquel XR, Luvox CR, Risperdal M-Tab, Zyprexa Zydis, Abilify Discmelt, Pristiq, and Invega 3. Prior Authorization (PA) requirements recommended for those drugs in Nonpreferred with Conditions mean that the member must have a trial and failure of the parent compound. Classification of Recommendations I. Drugs A. Brand Name Products 1) Pexeva Non-Preferred 2) Metadate CD Non-Preferred 3) Ritalin LA Non-Preferred B. Extended Release Products* 1) Luvox CR Non-Preferred 2) Seroquel XR Non-Preferred C. Different Dosage Forms of Preferred Products* 1) Risperdal M-Tab Non-Preferred 2) Zyprexa Zydis Non-Preferred 3) Abilify Discmelt Non-Preferred D. Metabolites of Preferred Products* 1) Invega Non-Preferred 2) Pristiq Non-Preferred *With Conditions II. Prior Authorization Requirements Recommended Nonpreferred with Conditions mean that the member must have a trial and failure of the parent compound. 1 Conditions refers to the clinical prior authorization criteria developed and recommended by the DUR Commission that require specific medical criteria and guidelines be met as a condition for prior authorization approval.

4

5

6

7

8

9 Extended Release Formulations Existing PA Criteria Payment for the extended release formulation will be considered only for cases in which there is documentation of previous trial and therapy failure with the immediate release product of the same chemical entity, unless evidence is provided that use of the immediate release product would be medically contraindicated. Prior authorization is required for the following extended release formulation(s): 1) Luvox CR 2) Seroquel XR Proposed PA Criteria Payment for a non-preferred extended release formulation will be considered only for cases in which there is documentation of a previous trial and therapy failure with the immediate release product of the same chemical entity, unless evidence is provided that use of the immediate release product would be medically contraindicated. Drugs to be affected: Adoxa, Amrix, Allegra D 24 hr, Brovex CT, Cardura XL, Cipro XR, Coreg CR, diclofenac ER, Doryx, etodolac ER/CR, Extendryl SR, Flagyl ER, glipizide ER, Glucotrol XL, indomethacin ER, InnoPran XL, Luvox CR, Metadate CD, Opana ER, Prozac Weekly, Quibron-T/SR, Requip XL, Ritalin LA, Seroquel XR, Sinemet CR, Solodyn ER, Ultram ER, Xanax XR*. *Currently included on the Benzodiazepine Prior Authorization form

10 Modified Formulations At the November 13 th P&T Committee Meeting, the members of the P&T Committee requested the DUR Commission develop clinical prior authorization criteria for the medications currently on the Recommended Drug List which will be moving to the Preferred Drug List. These medications are modified formulations of existing products. This was originally discussed at the May 2008 DUR Meeting. Proposed PA Criteria Payment for an isomer, pro-drug, metabolite, and/or alternative delivery system will only be considered for cases in which there is documentation of a recent trial and therapy failure with the original parent drug product of the same chemical entity, unless evidence is provided that use of the original product would be medically contraindicated. Prior Authorization is required for the following modified formulations: 1) Invega 4) Zyprexa Zydis 2) Pristiq 5) Abilify Discmelt 3) Risperdal-M Tabs

11 Iowa DUR Claims Outside of Monthly Quantity Limits on Acetaminophen-Containing Analgesics for the Period of 07/01/2008 to 11/30/2008 *Suggested quantity limits are based on the maximum daily dose of acetaminophen (4000mg per 24 hours). Drug Description Qty Limit* Member Count Claim Count Paid Amt Acetaminophen Tab 500 MG $ Hydrocodone-Acetaminophen Tab MG $ Hydrocodone-Acetaminophen Tab MG $ Hydrocodone-Acetaminophen Tab MG $37.50 Oxycodone w/ Acetaminophen Tab MG $47.37 Propoxyphene-N w/ APAP Tab MG $1, $2, RT

12 Iowa DUR Claims Outside of Daily Quantity Limits on Acetaminophen-Containing Analgesics for the Period of 07/01/2008 to 11/30/2008 *Suggested quantity limits are based on the maximum daily dose of acetaminophen (4000mg per 24 hours). Daily Qty Drug Description Limit Member Count Claim Count Paid Amt Pentazocine w/ APAP Tab MG $53.80 Hydrocodone-Acetaminophen Tab MG $81.48 Hydrocodone-Acetaminophen Tab MG $ Tramadol-Acetaminophen Tab MG $ Oxycodone w/ Acetaminophen Tab MG $1, Oxycodone w/ Acetaminophen Tab MG $ Oxycodone w/ Acetaminophen Tab MG $ Acetaminophen w/ Codeine Tab MG $47.84 Hydrocodone-Acetaminophen Tab MG 8 3,817 5,283 $29, Hydrocodone-Acetaminophen Tab MG $ Propoxyphene-N w/ APAP Tab MG $56.22 Propoxyphene-N w/ APAP Tab MG 6 1,526 2,196 $23, Butalbital-Acetaminophen-Caffeine Tab $ MG Acetaminophen Tab 500 MG $1, Hydrocodone-Acetaminophen Tab MG $42.16 Butalbital-Acetaminophen-Caff w/ COD Cap $ MG Hydrocodone-Acetaminophen Tab MG $6, Hydrocodone-Acetaminophen Tab MG $1, Oxycodone w/ Acetaminophen Tab MG $96.41 Butalbital-Acetaminophen Tab MG $11.62 Acetaminophen w/ Codeine Tab MG $4, Butalbital-Acetaminophen-Caffeine Tab $ MG Acetaminophen w/ Codeine Soln MG/5ML $ RT

13 Daily Qty Drug Description Limit Member Count Claim Count Paid Amt Hydrocodone-Acetaminophen Tab MG $4, Hydrocodone-Acetaminophen Tab MG $2, Oxycodone w/ Acetaminophen Cap MG $ Oxycodone w/ Acetaminophen Tab MG $7, Acetaminophen w/ Codeine Tab MG $6.57 Hydrocodone-Acetaminophen Tab MG $3, Hydrocodone-Acetaminophen Soln $4, MG/15ML Hydrocodone-Acetaminophen Tab MG $ Hydrocodone-Acetaminophen Tab MG $ Oxycodone w/ Acetaminophen Tab MG $ ,333 11,348 $96, RT

14 Iowa DUR Select Members with Utilization in Narcotics - Misc, Narcotics - Selected, Analgesics - Misc and/or NSAIDS PDL Categories for the Period of 08/01/2008 to 11/30/2008 Purpose: To look at those members identified as exceeding the proposed quantity limits for the short acting narcotics, who may also be taking one or more drugs from the following PDL categories: narcotics - misc, narcotics - selected, analgesics - misc, and/or NSAIDS. RX Num DOS Qty Days Supply Drug Description RX Num DOS Qty Days Supply Drug Description Member: Z /15/ /15/ /10/ /10/ Member: Z /01/ IBUPROFEN TAB 600MG /15/ /01/ IBUPROFEN TAB 600MG /16/ /06/ /25/ /03/ IBUPROFEN TAB 600MG Member: Z /19/ /16/ /20/ /11/ HYDROCO/APAP TAB 5-500MG /17/ Member: Z /30/ /25/ Member: Z /06/ /26/ /23/ /26/ SULINDAC TAB 200MG /24/ /20/ DICLOFENAC TAB 75MG DR Member: Z /18/ HYDROCO/APAP TAB /12/ HYDROCO/APAP TAB /03/ SULINDAC TAB 200MG /09/ HYDROCO/APAP TAB /05/ HYDROCO/APAP TAB /05/ TRAMADOL HCL TAB 50MG /28/ TRAMADOL HCL TAB 50MG Member: Z /12/ TRAMADOL HCL TAB 50MG /19/ /13/ /12/ HYDROCO/APAP TAB 5-500MG /14/ /11/ RT

15 RX Num DOS Qty Days Supply Drug Description RX Num DOS Qty Days Supply Drug Description Member: Z /08/ HYDROCO/APAP TAB 5-500MG /05/ OXYCOD/APAP TAB 5-325MG /30/ OXYCOD/APAP TAB 5-325MG /28/ OXYCOD/APAP TAB 5-325MG /26/ OXYCOD/APAP TAB 5-325MG Member: Z /30/ /05/ OXYCOD/APAP TAB 5-325MG /17/ Member: Z /01/ GENEBS TAB 325MG /01/ ASPIRIN TAB 325MG /01/ TRAMADOL HCL TAB 50MG /07/ APAP/CODEINE TAB MG /12/ TRAMADOL HCL TAB 50MG /13/ VOLTAREN GEL 1% /01/ ASPIRIN TAB 325MG /01/ TRAMADOL HCL TAB 50MG /02/ ASPIRIN TAB 325MG EC /02/ TRAMADOL HCL TAB 50MG /11/ HYDROCO/APAP TAB 5-500MG /02/ HYDROCO/APAP TAB 5-500MG /02/ TRAMADOL HCL TAB 50MG /10/ IBUPROFEN TAB 600MG /04/ HYDROCO/APAP TAB 5-500MG /04/ IBUPROFEN TAB 600MG /04/ TRAMADOL HCL TAB 50MG Member: Z /15/ HYDROCO/APAP TAB MG /20/ HYDROCO/APAP TAB MG Member: Z /21/ INDOMETHACIN CAP 50MG /21/ /17/ /17/ ASPIRIN TAB 81MG EC /11/ INDOMETHACIN CAP 50MG /13/ /16/ ASA LOW DOSE TAB 81MG EC /10/ INDOMETHACIN CAP 50MG /10/ ASA LOW DOSE TAB 81MG EC /10/ Member: Z /16/ Member: Z /26/ HYDROCO/APAP TAB /03/ HYDROCO/APAP TAB /06/ HYDROCO/APAP TAB /17/ HYDROCO/APAP TAB Member: Z /18/ OXYCOD/APAP TAB 5-325MG /17/ OXYCOD/APAP TAB 5-325MG /16/ OXYCOD/APAP TAB 5-325MG /29/ OXYCOD/APAP TAB 5-325MG /17/ OXYCOD/APAP TAB 5-325MG Member: Z RT

16 Distinct Clients 16 RT

17 IOWA DUR Clozapine/Fazaclo Study for the Period of 5/1/2008 to 12/31/2008 Purpose: To identify new starters of clozapine and follow monitoring for White Blood Count (WBC), Absolute Neutrophil Count (ANC), and clozapine blood levels. A secondary purpose was to determine the effect, if any, of clozapine use on doses of atypical antipsychotics. Note: Drugs and Procedures are shown in the same column. Procedures are highlighted. DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/15/ CLOZAPINE TAB 100MG 12/15/ CLOZAPINE TAB 25MG 11/18/ CLOZAPINE TAB 25MG 11/10/ CLOZAPINE TAB 100MG 10/20/ CLOZAPINE TAB 100MG 10/20/ CLOZAPINE TAB 25MG 09/22/ CLOZAPINE TAB 25MG 09/22/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 25MG 07/28/ CLOZAPINE TAB 25MG 07/28/ CLOZAPINE TAB 100MG 07/07/ CLOZAPINE TAB 100MG 07/07/ CLOZAPINE TAB 25MG Z 12/14/ FAZACLO TAB 100MG 12/14/ SEROQUEL TAB 200MG 11/14/ FAZACLO TAB 100MG 11/14/ SEROQUEL TAB 200MG 11/11/ SEROQUEL TAB 200MG 11/11/ FAZACLO TAB 100MG 10/15/ FAZACLO TAB 100MG 10/14/ SEROQUEL TAB 300MG 10/08/ FAZACLO TAB 100MG 09/14/ SEROQUEL TAB 300MG 09/14/ CLOZAPINE TAB 100MG 08/20/ CLOZAPINE TAB 100MG 08/14/ SEROQUEL TAB 300MG 08/14/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 100MG 07/14/ SEROQUEL TAB 300MG 07/11/ SEROQUEL TAB 300MG 06/14/ SEROQUEL TAB 200MG 05/14/ SEROQUEL TAB 200MG RT

18 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/26/ CLOZAPINE TAB 100MG 12/17/ CLOZAPINE TAB 100MG 12/15/ /12/ CLOZAPINE TAB 100MG 12/05/ CLOZAPINE TAB 100MG 11/28/ CLOZAPINE TAB 100MG 11/21/ CLOZAPINE TAB 100MG 11/14/ CLOZAPINE TAB 100MG 11/07/ CLOZAPINE TAB 100MG 10/31/ CLOZAPINE TAB 100MG 10/25/ CLOZAPINE TAB 100MG 10/17/ CLOZAPINE TAB 100MG 10/10/ CLOZAPINE TAB 100MG 10/06/ /03/ CLOZAPINE TAB 100MG 09/26/ CLOZAPINE TAB 100MG 09/19/ CLOZAPINE TAB 100MG 09/13/ CLOZAPINE TAB 100MG 09/05/ CLOZAPINE TAB 100MG 08/29/ CLOZAPINE TAB 100MG 08/22/ CLOZAPINE TAB 100MG 08/15/ CLOZAPINE TAB 100MG 08/08/ CLOZAPINE TAB 100MG 07/30/ CLOZAPINE TAB 100MG 07/22/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 100MG 07/09/ CLOZAPINE TAB 100MG 07/02/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 25MG 06/27/ CLOZAPINE TAB 25MG 06/20/ CLOZAPINE TAB 25MG 06/13/ CLOZAPINE TAB 25MG 06/06/ CLOZAPINE TAB 25MG 05/30/ CLOZAPINE TAB 25MG 05/16/ RISPERDAL TAB 2MG RT

19 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/22/ RISPERDAL INJ 50MG 12/11/ CLOZAPINE TAB 25MG 12/11/ INVEGA TAB 6MG 12/08/ RISPERDAL INJ 50MG 11/22/ RISPERDAL INJ 50MG 11/14/ CLOZAPINE TAB 25MG 11/14/ RISPERDAL TAB 4MG 11/14/ INVEGA TAB 6MG 11/11/ RISPERDAL INJ 50MG 10/27/ RISPERDAL INJ 50MG 10/17/ CLOZAPINE TAB 25MG 10/16/ RISPERDAL TAB 4MG 10/13/ RISPERDAL INJ 50MG 09/26/ RISPERDAL INJ 50MG 09/22/ RISPERDAL TAB 4MG 09/22/ CLOZAPINE TAB 25MG 09/15/ RISPERDAL INJ 50MG 09/03/ RISPERDAL INJ 50MG 08/21/ RISPERDAL TAB 4MG 08/21/ CLOZAPINE TAB 25MG 08/20/ RISPERDAL INJ 50MG 08/01/ RISPERDAL INJ 50MG 07/23/ RISPERIDONE TAB 4MG 07/22/ RISPERDAL INJ 50MG 07/22/ CLOZAPINE TAB 25MG 07/09/ RISPERDAL INJ 50MG 06/26/ RISPERDAL INJ 50MG 06/25/ RISPERDAL TAB 4MG 06/25/ CLOZAPINE TAB 25MG 06/04/ RISPERDAL TAB 4MG 06/04/ RISPERDAL INJ 50MG 05/08/ RISPERDAL TAB 4MG 05/01/ RISPERDAL INJ 50MG RT

20 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/19/ CLOZAPINE TAB 100MG 12/19/ CLOZAPINE TAB 25MG 12/18/ /25/ CLOZAPINE TAB 100MG 11/25/ CLOZAPINE TAB 25MG 11/21/ /29/ CLOZAPINE TAB 25MG 10/29/ CLOZAPINE TAB 100MG 10/28/ /27/ /01/ CLOZAPINE TAB 25MG 10/01/ CLOZAPINE TAB 100MG 09/29/ /03/ CLOZAPINE TAB 100MG 09/03/ CLOZAPINE TAB 25MG 09/02/ /04/ CLOZAPINE TAB 25MG 08/04/ CLOZAPINE TAB 100MG 08/01/ /22/ CLOZAPINE TAB 25MG 07/22/ CLOZAPINE TAB 100MG 07/09/ CLOZAPINE TAB 25MG 07/09/ CLOZAPINE TAB 100MG 07/07/ /25/ CLOZAPINE TAB 25MG 06/25/ CLOZAPINE TAB 100MG 06/24/ Z 12/27/ /20/ /13/ /06/ /29/ /22/ /15/ /08/ /01/ /25/ /20/ /11/ /04/ /27/ /20/ /13/ /06/ /30/ /25/ /16/ /09/ /02/ /26/ /19/ /12/ /05/ /02/ RT

21 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/17/ CLOZAPINE TAB 25MG 12/16/ /23/ CLOZAPINE TAB 25MG 11/07/ CLOZAPINE TAB 25MG 10/31/ CLOZAPINE TAB 25MG 10/24/ CLOZAPINE TAB 25MG 10/17/ CLOZAPINE TAB 25MG 10/17/ /10/ CLOZAPINE TAB 25MG 10/03/ CLOZAPINE TAB 25MG 10/02/ /09/ ABILIFY TAB 30MG 06/25/ ABILIFY TAB 30MG 06/06/ ABILIFY TAB 30MG 05/30/ ABILIFY TAB 30MG Z 12/08/ CLOZAPINE TAB 100MG 12/08/ CLOZAPINE TAB 100MG 12/08/ CLOZAPINE TAB 200MG 11/22/ CLOZAPINE TAB 25MG 11/22/ CLOZAPINE TAB 100MG 11/07/ CLOZAPINE TAB 100MG 11/07/ CLOZAPINE TAB 25MG 10/24/ CLOZAPINE TAB 25MG 10/24/ CLOZAPINE TAB 100MG 10/13/ CLOZAPINE TAB 100MG 10/13/ CLOZAPINE TAB 25MG 09/30/ CLOZAPINE TAB 100MG 09/30/ CLOZAPINE TAB 25MG 09/16/ CLOZAPINE TAB 25MG 09/16/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 100MG 08/28/ CLOZAPINE TAB 25MG 08/15/ CLOZAPINE TAB 100MG 08/15/ CLOZAPINE TAB 25MG 08/01/ CLOZAPINE TAB 25MG 08/01/ CLOZAPINE TAB 100MG 07/21/ CLOZAPINE TAB 100MG 07/21/ CLOZAPINE TAB 25MG 07/08/ CLOZAPINE TAB 25MG 07/08/ CLOZAPINE TAB 100MG 06/24/ CLOZAPINE TAB 100MG 06/24/ CLOZAPINE TAB 25MG 06/09/ CLOZAPINE TAB 25MG 06/09/ CLOZAPINE TAB 100MG 05/27/ CLOZAPINE TAB 25MG 05/27/ CLOZAPINE TAB 100MG RT

22 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/24/ FAZACLO TAB 100MG 12/24/ FAZACLO TAB 25MG 12/09/ FAZACLO TAB 100MG 11/24/ FAZACLO TAB 100MG 11/12/ FAZACLO TAB 100MG 10/28/ FAZACLO TAB 100MG 10/14/ FAZACLO TAB 100MG 09/30/ FAZACLO TAB 100MG 09/16/ FAZACLO TAB 100MG 09/05/ FAZACLO TAB 100MG 08/19/ FAZACLO TAB 100MG 08/18/ FAZACLO TAB 100MG 08/12/ FAZACLO TAB 25MG 07/08/ SEROQUEL XR TAB 400MG 06/20/ SEROQUEL XR TAB 300MG 05/16/ SEROQUEL XR TAB 300MG Z 12/20/ CLOZAPINE TAB 25MG 12/07/ CLOZAPINE TAB 25MG 12/05/ /05/ LEUKOCYTE (WBC) AUTOMATE 11/23/ CLOZAPINE TAB 25MG 11/21/ /21/ LEUKOCYTE (WBC) AUTOMATE 11/07/ LEUKOCYTE (WBC) AUTOMATE 11/07/ /07/ CLOZAPINE TAB 25MG 10/24/ /24/ LEUKOCYTE (WBC) AUTOMATE 10/23/ CLOZAPINE TAB 25MG 10/12/ CLOZAPINE TAB 25MG 10/10/ LEUKOCYTE (WBC) AUTOMATE 10/10/ /25/ /25/ LEUKOCYTE (WBC) AUTOMATE 09/25/ CLOZAPINE TAB 25MG 09/12/ CLOZAPINE TAB 25MG 09/12/ /31/ CLOZAPINE TAB 25MG 08/28/ /28/ LEUKOCYTE (WBC) AUTOMATE 08/17/ CLOZAPINE TAB 25MG 08/15/ /15/ LEUKOCYTE (WBC) AUTOMATE RT

23 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 10/10/ ZYPREXA TAB 10MG 09/06/ CLOZAPINE TAB 100MG 09/03/ ZYPREXA ZYDI TAB 10MG 08/30/ CLOZAPINE TAB 25MG 07/25/ /10/ CLOZAPINE TAB 25MG 07/10/ CLOZAPINE TAB 100MG 07/04/ CLOZAPINE TAB 100MG 06/28/ CLOZAPINE TAB 100MG 06/23/ CLOZAPINE TAB 100MG 06/18/ /16/ CLOZAPINE TAB 100MG 06/13/ CLOZAPINE TAB 25MG 06/07/ CLOZAPINE TAB 25MG 06/02/ CLOZAPINE TAB 25MG Z 12/17/ CLOZAPINE TAB 100MG 11/24/ CLOZAPINE TAB 100MG 11/06/ CLOZAPINE TAB 100MG 10/27/ CLOZAPINE TAB 100MG 10/10/ CLOZAPINE TAB 100MG 09/26/ CLOZAPINE TAB 100MG 09/05/ CLOZAPINE TAB 100MG 08/15/ CLOZAPINE TAB 100MG 07/28/ CLOZAPINE TAB 100MG 07/16/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 100MG RT

24 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/23/ ABILIFY TAB 15MG 12/23/ ABILIFY TAB 10MG 12/23/ CLOZAPINE TAB 100MG 12/11/ ABILIFY TAB 20MG 11/24/ CLOZAPINE TAB 100MG 11/19/ /13/ /10/ ZYPREXA TAB 10MG 11/07/ /31/ /23/ /16/ /11/ ZYPREXA TAB 10MG 10/10/ /03/ /26/ /20/ /11/ /11/ ZYPREXA TAB 10MG 09/06/ /29/ /12/ ZYPREXA TAB 10MG 07/31/ CLOZAPINE TAB 100MG 07/30/ ZYPREXA TAB 20MG 06/20/ ZYPREXA TAB 20MG 06/20/ SEROQUEL TAB 400MG 05/23/ SEROQUEL TAB 400MG 05/23/ ZYPREXA TAB 20MG 05/12/ SEROQUEL TAB 400MG 05/12/ ZYPREXA TAB 20MG RT

25 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/31/ CLOZAPINE TAB 100MG 12/12/ CLOZAPINE TAB 200MG 12/12/ CLOZAPINE TAB 25MG 12/12/ CLOZAPINE TAB 50MG 12/11/ CLOZAPINE TAB 100MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 200MG 12/01/ CLOZAPINE TAB 25MG 11/26/ CLOZAPINE TAB 200MG 11/26/ CLOZAPINE TAB 25MG 11/26/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 25MG 11/01/ CLOZAPINE TAB 200MG 10/20/ CLOZAPINE TAB 25MG 10/20/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 10/01/ CLOZAPINE TAB 50MG 09/02/ CLOZAPINE TAB 200MG 09/02/ CLOZAPINE TAB 50MG 08/22/ CLOZAPINE TAB 50MG 08/22/ CLOZAPINE TAB 200MG 08/01/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 50MG 07/17/ CLOZAPINE TAB 100MG 07/17/ CLOZAPINE TAB 100MG 07/07/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 25MG 07/01/ CLOZAPINE TAB 100MG 06/17/ CLOZAPINE TAB 100MG 06/02/ CLOZAPINE TAB 50MG 06/02/ ABILIFY TAB 10MG 06/02/ CLOZAPINE TAB 25MG 06/01/ GEODON CAP 80MG 06/01/ ABILIFY TAB 20MG 05/01/ GEODON CAP 80MG 05/01/ GEODON CAP 40MG 05/01/ ABILIFY TAB 20MG Z 12/30/ CLOZAPINE TAB 25MG 11/28/ CLOZAPINE TAB 25MG 10/27/ CLOZAPINE TAB 100MG 09/20/ CLOZAPINE TAB 100MG 08/21/ CLOZAPINE TAB 100MG 07/22/ CLOZAPINE TAB 100MG 06/26/ CLOZAPINE TAB 100MG 06/12/ CLOZAPINE TAB 25MG 06/11/ SEROQUEL TAB 100MG Z 12/01/ CLOZAPINE TAB 100MG 11/03/ CLOZAPINE TAB 100MG 10/01/ CLOZAPINE TAB 100MG 09/03/ CLOZAPINE TAB 100MG 08/01/ CLOZAPINE TAB 100MG 07/02/ CLOZAPINE TAB 100MG 06/26/ CLOZAPINE TAB 100MG RT

26 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/22/ CLOZAPINE TAB 100MG 12/08/ CLOZAPINE TAB 100MG 11/25/ CLOZAPINE TAB 100MG 11/11/ CLOZAPINE TAB 200MG 11/11/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 200MG 11/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 200MG 07/12/ CLOZAPINE TAB 50MG 07/09/ CLOZAPINE TAB 25MG 07/09/ CLOZAPINE TAB 200MG 07/01/ CLOZAPINE TAB 100MG 07/01/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 200MG 06/25/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 50MG 06/01/ CLOZAPINE TAB 200MG 05/28/ CLOZAPINE TAB 100MG 05/28/ CLOZAPINE TAB 50MG 05/28/ CLOZAPINE TAB 200MG 05/23/ CLOZAPINE TAB 25MG 05/23/ CLOZAPINE TAB 100MG RT

27 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/29/ CLOZAPINE TAB 100MG 12/29/ CLOZAPINE TAB 50MG 12/24/ CLOZAPINE TAB 100MG 12/24/ CLOZAPINE TAB 50MG 12/24/ GEODON CAP 40MG 12/20/ CLOZAPINE TAB 100MG 12/20/ CLOZAPINE TAB 50MG 12/20/ GEODON CAP 40MG 12/06/ CLOZAPINE TAB 100MG 12/06/ CLOZAPINE TAB 50MG 12/06/ GEODON CAP 40MG 11/30/ GEODON CAP 40MG 11/30/ CLOZAPINE TAB 100MG 11/30/ CLOZAPINE TAB 50MG 11/27/ CLOZAPINE TAB 100MG 11/27/ CLOZAPINE TAB 50MG 11/27/ GEODON CAP 40MG 11/26/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 50MG 11/26/ GEODON CAP 40MG 11/22/ CLOZAPINE TAB 100MG 11/22/ CLOZAPINE TAB 50MG 11/22/ GEODON CAP 40MG 11/01/ CLOZAPINE TAB 100MG 11/01/ GEODON CAP 40MG 11/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 50MG 10/01/ GEODON CAP 40MG 10/01/ CLOZAPINE TAB 100MG 09/30/ CLOZAPINE TAB 50MG 09/12/ CLOZAPINE TAB 25MG 09/12/ CLOZAPINE TAB 100MG 09/04/ GEODON CAP 40MG 09/02/ GEODON CAP 40MG 09/02/ CLOZAPINE TAB 100MG 09/02/ CLOZAPINE TAB 25MG 08/19/ CLOZAPINE TAB 25MG 08/19/ CLOZAPINE TAB 50MG 08/13/ GEODON CAP 40MG 08/06/ GEODON CAP 20MG 08/06/ GEODON CAP 60MG 08/01/ GEODON CAP 40MG 07/16/ ABILIFY TAB 10MG 07/16/ GEODON CAP 20MG 07/16/ GEODON CAP 40MG 07/16/ GEODON CAP 40MG 07/02/ GEODON CAP 40MG 07/01/ ABILIFY TAB 20MG 07/01/ ABILIFY TAB 5MG 06/01/ ABILIFY TAB 20MG 06/01/ ABILIFY TAB 5MG 05/01/ ABILIFY TAB 20MG 05/01/ ABILIFY TAB 5MG RT

28 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/24/ CLOZAPINE TAB 200MG 12/24/ CLOZAPINE TAB 50MG 12/14/ CLOZAPINE TAB 200MG 12/14/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 200MG 11/01/ CLOZAPINE TAB 50MG 10/06/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 200MG 08/20/ CLOZAPINE TAB 25MG 08/20/ CLOZAPINE TAB 200MG 08/07/ CLOZAPINE TAB 25MG 08/07/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 100MG 07/28/ CLOZAPINE TAB 25MG 07/28/ CLOZAPINE TAB 100MG 07/09/ CLOZAPINE TAB 100MG 07/08/ CLOZAPINE TAB 100MG 07/08/ CLOZAPINE TAB 25MG 07/03/ CLOZAPINE TAB 25MG 07/03/ CLOZAPINE TAB 100MG 06/25/ CLOZAPINE TAB 100MG 06/25/ CLOZAPINE TAB 25MG 06/18/ CLOZAPINE TAB 25MG 06/18/ CLOZAPINE TAB 100MG 06/12/ CLOZAPINE TAB 25MG 06/12/ CLOZAPINE TAB 100MG 06/05/ CLOZAPINE TAB 100MG 06/05/ CLOZAPINE TAB 25MG 05/29/ CLOZAPINE TAB 100MG 05/29/ CLOZAPINE TAB 25MG 05/22/ CLOZAPINE TAB 100MG 05/22/ CLOZAPINE TAB 25MG Z 12/23/ CLOZAPINE TAB 50MG 12/23/ CLOZAPINE TAB 100MG 12/23/ CLOZAPINE TAB 50MG 12/17/ CLOZAPINE TAB 100MG 12/06/ CLOZAPINE TAB 50MG 12/03/ CLOZAPINE TAB 25MG 12/01/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 100MG 11/01/ CLOZAPINE TAB 100MG 10/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 100MG 10/01/ ABILIFY TAB 5MG 09/25/ CLOZAPINE TAB 50MG 09/25/ CLOZAPINE TAB 100MG 09/25/ ABILIFY TAB 5MG 09/08/ CLOZAPINE TAB 25MG 09/08/ ABILIFY TAB 10MG 09/08/ CLOZAPINE TAB 50MG 08/26/ ABILIFY TAB 15MG RT

29 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/31/ /29/ /24/ /18/ /10/ /10/ LEUKOCYTE (WBC) AUTOMATE 12/03/ /24/ LEUKOCYTE (WBC) AUTOMATE 11/22/ /21/ LEUKOCYTE (WBC) AUTOMATE 11/17/ /10/ /04/ /03/ LEUKOCYTE (WBC) AUTOMATE 10/30/ /29/ LEUKOCYTE (WBC) AUTOMATE 10/24/ /17/ /13/ LEUKOCYTE (WBC) AUTOMATE 10/10/ /06/ LEUKOCYTE (WBC) AUTOMATE 10/02/ /29/ LEUKOCYTE (WBC) AUTOMATE 09/25/ CLOZAPINE TAB 100MG 09/22/ LEUKOCYTE (WBC) AUTOMATE 09/15/ LEUKOCYTE (WBC) AUTOMATE 09/11/ CLOZAPINE TAB 25MG 09/11/ CLOZAPINE TAB 100MG 09/08/ LEUKOCYTE (WBC) AUTOMATE 08/28/ CLOZAPINE TAB 25MG 08/22/ LEUKOCYTE (WBC) AUTOMATE 08/07/ CLOZAPINE TAB 25MG 07/25/ CLOZAPINE TAB 25MG 07/24/ LEUKOCYTE (WBC) AUTOMATE RT

30 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/30/ CLOZAPINE TAB 200MG 12/30/ CLOZAPINE TAB 50MG 12/23/ CLOZAPINE TAB 200MG 12/23/ CLOZAPINE TAB 50MG 12/12/ CLOZAPINE TAB 200MG 12/12/ CLOZAPINE TAB 50MG 12/06/ CLOZAPINE TAB 200MG 12/05/ CLOZAPINE TAB 50MG 12/02/ CLOZAPINE TAB 50MG 12/02/ CLOZAPINE TAB 100MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 25MG 12/01/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 100MG 11/26/ CLOZAPINE TAB 25MG 11/26/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 100MG 11/01/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 25MG 10/14/ GEODON CAP 20MG 10/13/ CLOZAPINE TAB 50MG 10/10/ CLOZAPINE TAB 50MG 10/03/ CLOZAPINE TAB 100MG 10/01/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 25MG 10/01/ GEODON CAP 40MG 09/25/ CLOZAPINE TAB 25MG 09/25/ GEODON CAP 40MG 09/25/ CLOZAPINE TAB 50MG 09/01/ GEODON CAP 20MG 08/01/ GEODON CAP 20MG 07/01/ GEODON CAP 20MG RT

31 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/24/ CLOZAPINE TAB 200MG 12/20/ CLOZAPINE TAB 200MG 12/13/ CLOZAPINE TAB 200MG 12/06/ CLOZAPINE TAB 200MG 12/01/ CLOZAPINE TAB 50MG 11/30/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 200MG 11/27/ CLOZAPINE TAB 50MG 11/22/ CLOZAPINE TAB 200MG 11/22/ CLOZAPINE TAB 50MG 11/14/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 50MG 11/01/ CLOZAPINE TAB 200MG 10/25/ CLOZAPINE TAB 50MG 10/22/ CLOZAPINE TAB 25MG 10/07/ GEODON CAP 40MG 10/01/ GEODON CAP 80MG 10/01/ CLOZAPINE TAB 200MG 10/01/ GEODON CAP 40MG 09/01/ GEODON CAP 80MG 09/01/ GEODON CAP 40MG 09/01/ CLOZAPINE TAB 200MG 08/01/ GEODON CAP 40MG 08/01/ GEODON CAP 80MG 08/01/ CLOZAPINE TAB 200MG 07/24/ CLOZAPINE TAB 200MG 07/05/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 100MG 07/01/ GEODON CAP 80MG 07/01/ GEODON CAP 40MG 06/30/ CLOZAPINE TAB 100MG 06/27/ CLOZAPINE TAB 25MG 06/27/ CLOZAPINE TAB 50MG 06/03/ GEODON CAP 40MG 06/03/ GEODON CAP 80MG 06/02/ GEODON CAP 20MG 06/02/ CLOZAPINE TAB 50MG 06/02/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 200MG 06/01/ GEODON CAP 40MG 06/01/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 25MG 05/27/ CLOZAPINE TAB 200MG 05/27/ CLOZAPINE TAB 25MG 05/27/ CLOZAPINE TAB 100MG 05/22/ CLOZAPINE TAB 50MG 05/22/ CLOZAPINE TAB 25MG 05/22/ CLOZAPINE TAB 100MG 05/22/ RISPERDAL TAB 0.5MG 05/13/ RISPERDAL TAB 1MG 05/13/ CLOZAPINE TAB 25MG 05/13/ GEODON CAP 40MG 05/01/ RISPERDAL TAB 2MG 05/01/ RISPERDAL TAB 0.5MG 05/01/ GEODON CAP 40MG 05/01/ GEODON CAP 80MG RT

32 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/19/ CLOZAPINE TAB 100MG 11/24/ CLOZAPINE TAB 100MG 10/27/ CLOZAPINE TAB 100MG 09/26/ CLOZAPINE TAB 100MG 09/24/ CLOZAPINE TAB 100MG 08/27/ CLOZAPINE TAB 100MG 07/29/ CLOZAPINE TAB 100MG 07/28/ CLOZAPINE TAB 100MG 06/13/ CLOZAPINE TAB 100MG 06/13/ CLOZAPINE TAB 25MG 06/13/ CLOZAPINE TAB 50MG 06/02/ ZYPREXA TAB 10MG 06/02/ GEODON CAP 40MG 06/02/ GEODON CAP 80MG 06/02/ ZYPREXA TAB 5MG 05/29/ ZYPREXA TAB 2.5MG 05/29/ ZYPREXA TAB 5MG 05/29/ ZYPREXA TAB 10MG 05/10/ GEODON CAP 80MG 05/10/ GEODON CAP 20MG 05/01/ GEODON CAP 40MG 05/01/ GEODON CAP 60MG RT

33 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/29/ /22/ /22/ ABILIFY TAB 5MG 12/15/ /08/ /01/ /26/ ABILIFY TAB 5MG 11/24/ /15/ /10/ CLOZAPINE TAB 25MG 11/10/ CLOZAPINE TAB 100MG 10/27/ ABILIFY TAB 5MG 10/27/ CLOZAPINE TAB 200MG 10/27/ CLOZAPINE TAB 50MG 10/01/ CLOZAPINE TAB 200MG 10/01/ CLOZAPINE TAB 50MG 10/01/ ABILIFY TAB 5MG 09/01/ ABILIFY TAB 5MG 09/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 50MG 08/26/ ABILIFY TAB 2MG 08/26/ ABILIFY TAB 5MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 200MG 07/08/ CLOZAPINE TAB 25MG 07/08/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 200MG 07/01/ CLOZAPINE TAB 50MG 07/01/ CLOZAPINE TAB 100MG 06/25/ CLOZAPINE TAB 200MG 06/11/ RISPERDAL TAB 0.5MG 06/11/ CLOZAPINE TAB 100MG 06/01/ CLOZAPINE TAB 25MG 06/01/ CLOZAPINE TAB 50MG 06/01/ RISPERDAL TAB 1MG 05/20/ RISPERDAL TAB 1MG 05/20/ CLOZAPINE TAB 25MG 05/20/ CLOZAPINE TAB 50MG 05/06/ RISPERDAL TAB 2MG 05/06/ RISPERDAL TAB 3MG RT

34 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 11/13/ CLOZAPINE TAB 100MG 10/15/ CLOZAPINE TAB 25MG 10/14/ CLOZAPINE TAB 100MG 09/23/ CLOZAPINE TAB 200MG 09/23/ CLOZAPINE TAB 25MG 09/23/ CLOZAPINE TAB 100MG 09/01/ CLOZAPINE TAB 200MG 09/01/ CLOZAPINE TAB 25MG 08/12/ SEROQUEL TAB 100MG 08/12/ CLOZAPINE TAB 50MG 08/12/ CLOZAPINE TAB 200MG 08/08/ CLOZAPINE TAB 50MG 08/08/ CLOZAPINE TAB 100MG 08/08/ SEROQUEL TAB 100MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 100MG 08/01/ SEROQUEL TAB 100MG 08/01/ CLOZAPINE TAB 25MG 07/18/ CLOZAPINE TAB 50MG 07/18/ SEROQUEL TAB 100MG 07/03/ CLOZAPINE TAB 100MG 07/03/ CLOZAPINE TAB 25MG 07/03/ SEROQUEL TAB 200MG 06/24/ SEROQUEL TAB 300MG 06/01/ SEROQUEL TAB 200MG 06/01/ SEROQUEL TAB 100MG 05/12/ SEROQUEL TAB 200MG 05/01/ SEROQUEL TAB 100MG RT

35 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/01/ ABILIFY TAB 15MG 12/01/ CLOZAPINE TAB 50MG 12/01/ CLOZAPINE TAB 200MG 11/03/ ABILIFY TAB 10MG 11/03/ CLOZAPINE TAB 50MG 11/03/ CLOZAPINE TAB 200MG 10/08/ ABILIFY TAB 10MG 10/01/ CLOZAPINE TAB 100MG 10/01/ ABILIFY TAB 5MG 10/01/ CLOZAPINE TAB 50MG 09/29/ CLOZAPINE TAB 100MG 09/22/ CLOZAPINE TAB 100MG 09/09/ CLOZAPINE TAB 100MG 09/01/ CLOZAPINE TAB 50MG 09/01/ ABILIFY TAB 5MG 09/01/ CLOZAPINE TAB 200MG 08/27/ ABILIFY TAB 5MG 08/26/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 50MG 08/01/ CLOZAPINE TAB 200MG 07/16/ CLOZAPINE TAB 200MG 07/16/ CLOZAPINE TAB 25MG 07/16/ CLOZAPINE TAB 50MG 07/03/ CLOZAPINE TAB 25MG 07/01/ CLOZAPINE TAB 25MG 07/01/ CLOZAPINE TAB 200MG 06/26/ CLOZAPINE TAB 25MG 06/01/ CLOZAPINE TAB 200MG 06/01/ CLOZAPINE TAB 25MG 05/24/ CLOZAPINE TAB 200MG 05/12/ ABILIFY TAB 10MG 05/12/ CLOZAPINE TAB 50MG 05/07/ CLOZAPINE TAB 25MG 05/07/ CLOZAPINE TAB 100MG 05/07/ ABILIFY TAB 15MG RT

36 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code Z 12/29/ CLOZAPINE TAB 100MG 12/29/ /26/ RISPERDAL INJ 25MG 12/22/ CLOZAPINE TAB 100MG 12/22/ /15/ /15/ CLOZAPINE TAB 100MG 12/10/ RISPERDAL INJ 25MG 12/08/ CLOZAPINE TAB 100MG 12/08/ /02/ CLOZAPINE TAB 100MG 12/01/ /25/ CLOZAPINE TAB 100MG 11/24/ /18/ RISPERDAL INJ 25MG 11/18/ CLOZAPINE TAB 100MG 11/17/ /13/ RISPERDAL INJ 50MG 11/10/ CLOZAPINE TAB 100MG 11/10/ /04/ CLOZAPINE TAB 100MG 11/03/ /29/ RISPERDAL INJ 50MG 10/27/ CLOZAPINE TAB 100MG 10/27/ /20/ /20/ CLOZAPINE TAB 100MG 10/16/ RISPERDAL INJ 50MG 10/13/ CLOZAPINE TAB 100MG 10/13/ /08/ /07/ CLOZAPINE TAB 100MG 10/02/ FAZACLO TAB 100MG 10/01/ /30/ RISPERDAL INJ 50MG 09/25/ FAZACLO TAB 100MG 09/24/ /18/ FAZACLO TAB 100MG 09/17/ /15/ RISPERDAL INJ 50MG 09/11/ FAZACLO TAB 100MG 09/10/ /04/ FAZACLO TAB 100MG 09/04/ RISPERDAL INJ 50MG 09/03/ /28/ FAZACLO TAB 100MG 08/27/ INVEGA TAB 3MG 08/27/ /25/ RISPERDAL INJ 50MG 08/20/ /19/ FAZACLO TAB 100MG 08/13/ FAZACLO TAB 100MG 08/13/ /07/ FAZACLO TAB 100MG 08/06/ /05/ INVEGA TAB 3MG 08/05/ RISPERDAL INJ 50MG 07/30/ /24/ FAZACLO TAB 100MG 07/24/ INVEGA TAB 3MG 07/23/ RISPERDAL INJ 50MG RT

37 DOS RX_Num/ Quantity Days Supply Product/Procedure Description Proc Code 07/23/ /21/ FAZACLO TAB 100MG 07/21/ INVEGA TAB 3MG 07/18/ FAZACLO TAB 100MG 07/18/ INVEGA TAB 3MG 07/16/ /11/ INVEGA TAB 3MG 07/11/ FAZACLO TAB 100MG 07/09/ /03/ FAZACLO TAB 100MG 07/03/ INVEGA TAB 3MG 07/03/ RISPERDAL TAB 1MG 07/02/ /30/ RISPERDAL TAB 1MG 06/27/ FAZACLO TAB 100MG 06/25/ FAZACLO TAB 100MG 06/25/ RISPERDAL INJ 50MG 06/25/ /25/ LEUKOCYTE (WBC) AUTOMATE 06/23/ FAZACLO TAB 25MG 06/23/ FAZACLO TAB 100MG 06/19/ INVEGA TAB 3MG 06/18/ /17/ FAZACLO TAB 25MG 06/16/ FAZACLO TAB 25MG 06/16/ FAZACLO TAB 100MG 06/15/ FAZACLO TAB 100MG 06/15/ RISPERDAL TAB 1MG 06/11/ /11/ RISPERDAL INJ 50MG 06/04/ /29/ FAZACLO TAB 25MG 05/28/ RISPERDAL INJ 50MG 05/28/ /27/ FAZACLO TAB 25MG 05/23/ FAZACLO TAB 25MG 05/22/ FAZACLO TAB 100MG 05/22/ INVEGA TAB 3MG 05/22/ RISPERDAL TAB 2MG 05/21/ /14/ RISPERDAL INJ 50MG 05/14/ /08/ FAZACLO TAB 25MG 05/08/ FAZACLO TAB 100MG 05/07/ RT

Iowa Medicaid Mental Health Advisory Group Meeting February 13, Tentative Agenda

Iowa Medicaid Mental Health Advisory Group Meeting February 13, Tentative Agenda CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Mental Health Advisory Group Meeting February 13, 2009 Location: Iowa Medicaid

More information

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP

More information

U T I L I Z A T I O N E D I T S

U T I L I Z A T I O N E D I T S I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental

More information

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management

More information

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011 Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 211 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness

More information

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: January 21, 2016 Time: 9am-1:30pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Members

More information

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes May 5, 2010

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes May 5, 2010 Iowa Medicaid Drug Utilization Review Commission Meeting Minutes May 5, 2010 Attendees: Commission Members Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck, D.O., FAAP; Laurie Pestel, Pharm.D.;

More information

New Hampshire Healthy Families CLINICAL POLICY

New Hampshire Healthy Families CLINICAL POLICY New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:

More information

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017 Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

Antipsychotic Medications Age and Step Therapy

Antipsychotic Medications Age and Step Therapy Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana

More information

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017 Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

Medicaid Perspective

Medicaid Perspective Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:

More information

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine

More information

I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more

I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more NSAID steroid update Leo Semes, OD, FAAO I. Mechanisms of action the role of prostaglandins a. Mediators of inflammation b. and much more II. Topical NSAIDS ophthalmic application III. Oral NSAIDs a. Precautions

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this

More information

Pequot Health Care Opioid Analgesic Quantity Program*

Pequot Health Care Opioid Analgesic Quantity Program* Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02. Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder

More information

Drug Use Evaluation: Short Acting Opioids (SAO)

Drug Use Evaluation: Short Acting Opioids (SAO) Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service

More information

Section 2 Class III, IV & V Pharmaceuticals Page 13

Section 2 Class III, IV & V Pharmaceuticals Page 13 Section 2 Class III, IV & V Pharmaceuticals Page 13 ACETAMINOPHEN W/ CODEINE #3 30MG TABS (GENERIC TYLENOL) #100 41.99 ACETAMINOPHEN W/ CODEINE #3 30MG TABS #1000 298.99 ACETAMINOPHEN W/ CODEINE #4 60MG

More information

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Date: July 16, 2015 Time: 9am-1:30pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder

More information

New Product to Market: Lonhala Magnair

New Product to Market: Lonhala Magnair Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the May 17, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.

More information

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010 Iowa Medicaid Drug Utilization Review Commission Meeting Minutes March 3, 2010 Attendees: Commission Members Bruce Alexander, R.Ph., Pharm.D., BCPP; Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck,

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Antipsychotics A. Prescriptions That Require Prior Authorization Prescriptions for Antipsychotics

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder

More information

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations Kentucky Department for Medicaid Services Pharmacy and May 17, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting November 5, 2008

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting November 5, 2008 CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting November 5, 2008 Location: Iowa

More information

These reports were prepared pursuant to directive contained in Section 10 of Senate File 2425 which is listed below:

These reports were prepared pursuant to directive contained in Section 10 of Senate File 2425 which is listed below: CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR January 15, 2009 Michael Marshall Secretary of Senate State Capitol LOCAL Mark Brandsgard Chief

More information

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08. Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important

More information

HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET

HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: February, 2013 Most recently revised: December 2018 The Psychiatric Measure Set CMS

More information

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise

More information

Clinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.

Clinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02. Clinical Policy: (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: 08.01.15 Last Review Date: 02.19 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory

More information

Curbing Prescription Drug Abuse in Medicaid

Curbing Prescription Drug Abuse in Medicaid Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance

More information

Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Preferred Drug List Changes - UPDATE

Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Preferred Drug List Changes - UPDATE Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Drug List Changes - UPDATE Note: This article was previously published in the December 2014 Medicaid

More information

Commissioner for the Department for Medicaid Services Selections for Preferred Products

Commissioner for the Department for Medicaid Services Selections for Preferred Products Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for

More information

NorthSTAR. Pharmacy Manual

NorthSTAR. Pharmacy Manual NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Effective Date: 04.18 Last Review Date: 04.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

Avoid paying too much for your prescriptions

Avoid paying too much for your prescriptions Quality health plans & benefits Healthier living Financial well-being Intelligent solutions 2017 Aetna Rx Step Program Medicine List Avoid paying too much for your prescriptions It s important to try to

More information

A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse

A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse INVESTIGATIVE TEAM: STEERING COMMITTEE FOR THE TUFTS HEALTH CARE INSTITUTE ON OPIOID RISK MANAGEMENT

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: AZ.CP.PHAR.10.11.10 Effective Date: 07.16 Last Review Date: 09.12.18 Line of Business: Medicaid Arizona Revision Log See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log

More information

Prior Authorization for Opioid Products Indicated for Pain Management

Prior Authorization for Opioid Products Indicated for Pain Management Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy

More information

Follow-up to Previous Reviews. Foster Children Prescribers (Nurse Practitioner Practice Sites)

Follow-up to Previous Reviews. Foster Children Prescribers (Nurse Practitioner Practice Sites) 15 January 2015 1 Follow-up to Previous Reviews Foster Children Prescribers (Nurse Practitioner Practice Sites) 2 Foster Children Prescribers (Nurse Practitioner Practice Sites) 3 Ongoing Reviews Buprenorphine

More information

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met: Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: Jan. 16, 2014 Time: 9am-1pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:

More information

Neighborhood Medicaid Formulary Changes: June 2017

Neighborhood Medicaid Formulary Changes: June 2017 Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were

More information

Step Therapy Criteria

Step Therapy Criteria Tier 5 Formulary Step Therapy 2016 Updated: 05/24/2016 Effective: 06/01/2016 What is Step Therapy? Some prescription drugs require step therapy (ST). In some cases, the plan requires you to first try certain

More information

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the

More information

Texas Prior Authorization Program Clinical Edit Criteria

Texas Prior Authorization Program Clinical Edit Criteria Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if

More information

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy

Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy DRUG POLICY Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy BENEFIT APPLICATION Benefit determinations are based on the applicable contract language

More information

CONTRAINDICATIONS TABLE

CONTRAINDICATIONS TABLE CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis

More information

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage

More information

PROPOSED DUR CRITERIA FOR MANAGING OPIOID USE AND MINIMIZING RISK OF OVERDOSE

PROPOSED DUR CRITERIA FOR MANAGING OPIOID USE AND MINIMIZING RISK OF OVERDOSE BACKGROUND PROPOSED DUR CRITERIA FOR MANAGING OPIOID USE AND MINIMIZING RISK OF OVERDOSE In March, 2016, the CDC released the final version of their Guidelines for Prescribing Opioids for Chronic Pain.

More information

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Fareston) Reference Number: CP.PMN.126 Effective Date: 04.01.10 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5)

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5) IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Brian Couse, M.D. Date: February 10, 2015 Mark Graber, M.D., FACEP,

More information

Idaho DUR Board Meeting Minutes. Committee Member Present: Matthew Hyde, Pharm.D., Perry Brown M.D., Paul Cady, Pharm.D., Ryan Heyborne M.D.

Idaho DUR Board Meeting Minutes. Committee Member Present: Matthew Hyde, Pharm.D., Perry Brown M.D., Paul Cady, Pharm.D., Ryan Heyborne M.D. Date: February 16, 2017 Time: 9am-12:15pm Idaho DUR Board Meeting Minutes Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Perry Brown, M.D. Committee Member

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for

More information

Appendix D: Drug Tables

Appendix D: Drug Tables Appendix D: Drug Tables A. Short-acting, Orally Administered Opioids Table D-1: Use of Short-acting, Orally Administered Opioids in Adults [198] Additional Maximum APAP dose: 4000 mg/d (2000 mg/d in chronic

More information

Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents

Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents DRUG NAME INDICATIONS / ACCEPTABLE USES PRIOR STIMULANT/ADHD DRUGS Daytrana (methylphenidate) ADHD

More information

Optima Health Community Care (OHCC) Maximum Allowable Daily Dosage and Quantity Limits April - June 2018

Optima Health Community Care (OHCC) Maximum Allowable Daily Dosage and Quantity Limits April - June 2018 With the safety of our members in mind, we regularly review recommendations from the Food and Drug Administration (FDA) and evidence-based treatment guidelines from the medical literature with our Pharmacy

More information

Idaho DUR Board Meeting Minutes

Idaho DUR Board Meeting Minutes Idaho DUR Board Meeting Minutes Date: October 16, 2014 Time: 9am-2pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: Mark Turner, M.D. Committee Member Present:

More information

News & Views. Maryland Medicaid Mental Health Formulary Revisions. Responsible use of Intervention and Outcome Codes

News & Views. Maryland Medicaid Mental Health Formulary Revisions. Responsible use of Intervention and Outcome Codes Maryland Medicaid Pharmacy Program News & Views June 2009 Maryland Department of Health and Mental Hygiene / Office of Systems, Operations and Pharmacy Maryland Medicaid Mental Health Formulary Revisions

More information

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019 Step Therapy Date Effective: April 1, 2019 ANTICONVULSANTS APTIOM TABLET 200 MG ORAL APTIOM TABLET 400 MG ORAL APTIOM TABLET 600 MG ORAL APTIOM TABLET 800 MG ORAL BANZEL SUSPENSION 40 MG/ML ORAL BANZEL

More information

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL* Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

More information

Opioid Management Program May 2018

Opioid Management Program May 2018 Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily

More information

: Opioid Quantity Limits

: Opioid Quantity Limits March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: potassium (Zipsor), (Zorvolex) Reference Number: CP.CPA.280 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end

More information

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes October 5, 2011

Iowa Medicaid Drug Utilization Review Commission Meeting Minutes October 5, 2011 Iowa Medicaid Drug Utilization Review Commission Meeting Minutes October 5, 2011 Attendees: Commission Members Mark Graber, M.D., FACEP; Casey Clor, M.D. ; Craig Logemann, R.Ph., Pharm.D., BCPS; Sara Schutte-Schenck,

More information

SHIP TRAMADOL TO UNITED STATES

SHIP TRAMADOL TO UNITED STATES SHIP TRAMADOL TO UNITED STATES Ship Tramadol To United States What is the pill tramadol 50mg Dogs tramadol and benadryl Can u take tramadol with paracetamol and ibuprofen 4 50 mg tramadol Tramadol detox

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

PL CE LIVE February 2011 Forum

PL CE LIVE February 2011 Forum February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Presented by Sata Hackenbruck 6 August 2009 State of Oregon SAS Users Group Meeting

Presented by Sata Hackenbruck 6 August 2009 State of Oregon SAS Users Group Meeting Presented by Sata Hackenbruck 6 August 2009 State of Oregon SAS Users Group Meeting Explore following SAS text functions: COMPRESS TRANWRD SCAN Here is the problem I am analyzing pharmacy data and I want

More information

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

Pharmacy Medical Necessity Guidelines: Opioid Analgesics Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Cyclosporine is an immunosuppressant

Cyclosporine is an immunosuppressant Indiana Drug Utilization Review Board September, 1998 Issue No. 4 Generic Differences Associated with Cyclosporine Products Cyclosporine is an immunosuppressant agent used in the prophylaxis of organ rejection

More information

Nebraska Medicaid Criteria. Abilify Maintena

Nebraska Medicaid Criteria. Abilify Maintena Nebraska Medicaid Criteria All initial and renewal authorizations are for 12 months in duration. Abilify Maintena *Criteria for Authorization for Abilify Maintena The individual has a current DSM diagnosis

More information

Drug Utilization Review Board

Drug Utilization Review Board Drug Utilization Review Board Oklahoma Health Care Authority 2401 N.W. 23rd Street, Suite 1A Oklahoma City, Oklahoma 73107 Ponca Room Wednesday May 9, 2012 6:00 p.m. The University of Oklahoma Health Sciences

More information